Abstract
In type 2 diabetes mellitus (T2DM) patients, the gradual loss of pancreatic β-cell function is a characteristic feature of disease progression that is associated with sustained hyperglycemia. Recently, G protein-coupled receptor 119 (GPR119) has been identified as a promising anti-diabetic therapeutic target. It is predominantly expressed in pancreatic β-cells, directly promotes glucose stimulated insulin secretion and indirectly increases glucagon-like peptide 1 (GLP-1) levels reducing appetite and food intake. Activation of GPR119 leads to insulin release in β-cells by increasing intracellular cAMP. Here, we identified a novel structural class of small-molecule GPR119 agonists, HD0471042, consisting of substituted a 3-isopropyl-1,2,4-oxadiazol-piperidine derivative with promising potential for the treatment of T2DM. The GPR119 agonist, HD0471042 increased intracellular cAMP levels in stably human GPR119 expressing CHO cell lines and HIT-T15 cell lines, hamster β-cell line expressing endogenously GPR119. HD0471042, significantly elevated insulin release in INS-1 cells of rat pancreatic β-cell line. In in vivo experiments, a single dose of HD0471042 improved glucose tolerance. Insulin and GLP-1 level were increased in a dose-dependent manner. Treatment with HD0471042 for 6 weeks in diet induced obesity mice and for 4 weeks in ob/ob and db/db mice improved glycemic control and also reduced weight gain in a dose-dependent manner. These data demonstrate that the novel GPR119 agonist, HD0471042, not only effectively controlled glucose levels, but also had an anti-obesity effect, a feature observed with GLP-1. We therefore suggest that HD0471042 represents a new type of anti-diabetes agent with anti-obesity potential for the effective treatment of type 2 diabetes.
Similar content being viewed by others
References
Chu, Z.L., C. Carroll, J. Alfonso, V. Gutierrez, H. He, A. Lucman, M. Pedraza, H. Mondala, H. Gao, D. Bagnol, R. Chen, R.M. Jones, D.P. Behan, and J. Leonard. 2008. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149(5): 2038–2047.
Chu, Z.L., C. Carroll, R. Chen, J. Alfonso, V. Gutierrez, H. He, A. Lucman, C. Xing, K. Sebring, J. Zhou, B. Wagner, D. Unett, R.M. Jones, D.P. Behan, and J. Leonard. 2010. N-Oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Molecular Endocrinology 24(1): 161–170.
Chu, Z.L., R.M. Jones, H. He, C. Carroll, V. Gutierrez, A. Lucman, M. Moloney, H. Gao, H. Mondala, D. Bagnol, D. Unett, Y. Liang, K. Demarest, G. Semple, D.P. Behan, and J. Leonard. 2007. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148(6): 2601–2609.
Felber, J.P., and A. Golay. 2002. Pathways from obesity to diabetes. International Journal of Obesity and Related Metabolic Disorders 26(suppl 2): S39–S45.
Henquin, J.C. 2000. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49(11): 1751–1760.
Kesty, N.C., J.D. Roth, and D. Maggs. 2008. Hormone-based therapies in the regulation of fuel metabolism and body weight. Expert Opinion on Biological Therapy 8(11): 1733–1747.
Madiraju, S.R., and V. Poitout. 2007. G protein-coupled receptors and insulin secretion: 119 and counting. Endocrinology 148(6): 2598–2600.
Ohishi, T., and S. Yoshida. 2012. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 21(3): 321–328.
Prokopenko, I., M.I. McCarthy, and C.M. Lindgren. 2008. Type 2 diabetes: new genes, new understanding. Trends in Genetics 24(12): 613–621.
Sadry, S.A., and D.J. Drucker. 2013. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nature Reviews Endocrinology 9: 425–433.
Sakamoto, Y., H. Inoue, S. Kawakami, K. Miyawaki, T. Miyamoto, K. Mizuta, and M. Itakura. 2006. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochemical and Biophysical Research Communications 351(2): 474–480.
Semple, G., B. Fioravanti, G. Pereira, I. Calderon, J. Uy, K. Choi, Y. Xiong, A. Ren, M. Morgan, V. Dave, W. Thomsen, D.J. Unett, C. Xing, S. Bossie, C. Carroll, Z.L. Chu, A.J. Grottick, E.K. Hauser, J. Leonard, and R.M. Jones. 2008. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. Journal of Medicinal Chemistry 51(17): 5172–5175.
Singh, S., H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, and J.B. Segal. 2013. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case–control study. JAMA Internal Medicine 173(7): 534–539.
Stumvoll, M., B.J. Goldstein, and T.W. van Haeften. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365(9467): 1333–1346.
Turton, M.D., D. O’Shea, I. Gunn, S.A. Beak, C.M. Edwards, K. Meeran, S.J. Choi, G.M. Taylor, M.M. Heath, P.D. Lambert, J.P. Wilding, D.M. Smith, M.A. Ghatei, J. Herbert, and S.R. Bloom. 1996. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379(6560): 69–72.
Yoshida, S., T. Ohishi, T. Matsui, H. Tanaka, H. Oshima, Y. Yonetoku, and M. Shibasaki. 2010. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice. Biochemical and Biophysical Research Communications 402(2): 280–285.
Yoshida, S., T. Ohishi, T. Matsui, H. Tanaka, H. Oshima, Y. Yonetoku, and M. Shibasaki. 2011. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic beta-cell function. Diabetes, Obesity and Metabolism 13(1): 34–41.
Acknowledgments
This study was supported by ‘a Grant of Advance Technology Center (ATC), Project No.: 10042208’ of the Korea Ministry of Knowledge and Economy.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ha, TY., Kim, YS., Kim, C.H. et al. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus. Arch. Pharm. Res. 37, 671–678 (2014). https://doi.org/10.1007/s12272-013-0209-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-013-0209-0